Lessons learned from a SIRT2-selective inhibitor

Oncotarget. 2016 Apr 26;7(17):22971-2. doi: 10.18632/oncotarget.8502.
No abstract available

Keywords: COMPARE analysis; Myc; oncoprotein; sirtuin; targeted cancer therapy.

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Drug Evaluation, Preclinical / methods*
  • Histone Deacetylase Inhibitors / pharmacology*
  • Histone Deacetylase Inhibitors / therapeutic use
  • Humans
  • Mice
  • Molecular Targeted Therapy / methods*
  • Neoplasms / drug therapy*
  • Neoplasms / enzymology
  • Phenotype
  • Proto-Oncogene Proteins c-myc / biosynthesis
  • Proto-Oncogene Proteins c-myc / deficiency
  • Sirtuin 2 / antagonists & inhibitors*

Substances

  • Antineoplastic Agents
  • Histone Deacetylase Inhibitors
  • MYC protein, human
  • Proto-Oncogene Proteins c-myc
  • SIRT2 protein, human
  • Sirtuin 2